淡江大學機構典藏:Item 987654321/112720
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 62819/95882 (66%)
造訪人次 : 4005651      線上人數 : 439
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library & TKU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋


    請使用永久網址來引用或連結此文件: https://tkuir.lib.tku.edu.tw/dspace/handle/987654321/112720


    題名: Adjunctive Sarcosine plus Benzoate Improved Cognitive Function in Chronic Schizophrenia Patients with Constant Clinical Symptoms: A Randomised, Double-Blind, Placebo-Controlled Trial
    作者: Chun-Yuan Lin;Sun-Yuan Liang;Yue-Cung Chang;Shuo-Yen Ting;Ching-Ling Kao;Yu-Hsin Wu;Guochuan Tsai;Hsien-Yuan Lane
    關鍵詞: Schizophrenia;biological psychiatry;psychopharmacology;cognitive function;NMDA receptor
    日期: 2017-06
    上傳時間: 2018-03-02 12:10:51 (UTC+8)
    摘要: Objectives Hypofunction of NMDA receptor is implicated in the pathophysiology, particularly cognitive impairment, of schizophrenia. Sarcosine, a glycine transporter I (GlyT-1) inhibitor, and sodium benzoate, a d-amino acid oxidase (DAAO) inhibitor, can both enhance NMDA receptor-mediated neurotransmission. We proposed simultaneously inhibiting DAAO and GlyT-1 may be more effective than inhibition of either in improving the cognitive and global functioning of schizophrenia patients. Methods This study compared add-on sarcosine (2 g/day) plus benzoate (1 g/day) vs. sarcosine (2 g/day) for the clinical symptoms, as well as the cognitive and global functioning, of chronic schizophrenia patients in a 12-week, double-blind, randomised, placebo-controlled trial. Participants were measured with the Positive and Negative Syndrome Scale and the Global Assessment of Functioning Scale every 3 weeks. Seven cognitive domains, recommended by the Measurement and Treatment Research to Improve Cognition in Schizophrenia Committee, were measured at weeks 0 and 12. Results Adjunctive sarcosine plus benzoate, but not sarcosine alone, improved the cognitive and global functioning of patients with schizophrenia, even when their clinical symptoms had not improved. Conclusions This finding suggests N-methyl-d-aspartate receptor-enhancement therapy can improve the cognitive function of patients with schizophrenia, further indicating this pro-cognitive effect can be primary without improvement in clinical symptoms.
    關聯: The World Journal of Biological Psychiatry 18(5), p.357-368
    DOI: 10.3109/15622975.2015.1117654
    顯示於類別:[數學學系暨研究所] 期刊論文

    文件中的檔案:

    檔案 大小格式瀏覽次數
    index.html0KbHTML129檢視/開啟

    在機構典藏中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library & TKU Library IR teams. Copyright ©   - 回饋